Images Header 04 Detection

Detection

Advancing rapid detection and diagnostics.

Our cutting-edge nanotechnology offers fast, affordable, non-invasive, scalable point-of-care detection for numerous pathogens, including viruses like COVID-19, empowering governments, health agencies and individuals worldwide to identify infections and end outbreaks faster than ever before.

Zentek has exclusive worldwide rights to commercialize a rapid, saliva-based COVID-19 antigen testing technology.

This technology has been developed by a team of researchers at McMaster University under the guidance of Drs. Yingfu Li, John Brennan and Leyla Soleymani, who are recognized as global leaders in biosensing technologies, and their applications as point of care (POC) diagnostics.

The Aptamers are single-stranded DNA molecules capable of binding specifically with target molecules called antigens to detect if a person has COVID-19.  

Zentek is currently adopting its Detection Technology for commercial prototyping readiness for the detection of COVID-19 by Q1, 2022.

The advantages of Zentek's aptamer technology are:

  • Simplicity & Comfort – uses saliva rather than a nasal swab reducing aversion to testing and risk of error in the sampling process
  • Accuracy – impedance technology rather than lateral flow allows for sensitivity equivalent to a 36 count Rt PCR
  • Mobility – simple hardware lends itself to easy transport and high throughput, point-of-care testing
  • Speed – results in under 10 minutes
  • Low Cost – aptamers can be developed more quickly and cost effectively compared to antibodies allowing us to be highly competitive compared to currently available rapid detection tests now and into the future
  • Scalability – new aptamers can be developed to detect numerous other pathogens giving our technology the ability to enhance safety and empower businesses, governments and our healthcare providers well beyond COVID
Images Circle Artboard 8

We believe this an unmatched combination compared to what is available in the market today.

The global economy will benefit from mobile, fast, highly accurate and inexpensive testing and we expect this innovative technology to help facilitate this, including the ability to rapidly adapt new variants and other pathogens into the test.

Get In Touch

Commercial Partners

Are you interested in our technology to enhance your product offering - or have an innovation that fits well with our focus areas and would like to work together?

Contact

Ryan Shacklock

rshacklock@zentek.com

Government

Are you a member of federal, provincial or international governments looking to invest, fund, collaborate, partner with, support, or help advance next-gen healthcare?

Contact

Monique Manaigre

mmanaigre@zentek.com

Research Community

Are you a researcher focused on new and innovative nanotechnologies and looking for a highly engaged development partner?

Contact

Dr. Colin van der Kuur

cvanderkuur@zentek.com

Other Inquiries

Are you looking for other company information?

Contact

Sandra Lombardo

slombardo@zentek.com